Identification of quinazoline compounds as novel potent inhibitors of wnt/β-catenin signaling in colorectal cancer cells

Oncotarget

Volumn 7, Issue 10, 2016, Pages 11263-11270

  Li, Yonghe ^a   Lu, Wenyan ^a   Saini, Surendra K ^a   Moukha Chafiq, Omar ^a   Pathak, Vibha ^a   Ananthan, Subramaniam ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Colorectal cancer; Drug discovery; Quinazoline; Wnt inhibitor; Wnt signaling

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; QUINAZOLINE DERIVATIVE; SRI 20039; SRI 28875; SRI 28876; SRI 28998; SRI 29072; SRI 29155; SRI 29213; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APC GENE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CTNNB1 GENE; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; GENE; HUMAN; HUMAN CELL; IC50; SIGNAL TRANSDUCTION; COLORECTAL TUMOR; DRUG EFFECTS; DRUG SCREENING; METABOLISM; TUMOR CELL LINE; WNT SIGNALING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; QUINAZOLINES; WNT SIGNALING PATHWAY;

EID: 84962032677     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7019     Document Type: Article

References (34)

1. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13:11-26.
2. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149:1192-1205.
3. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012; 31:2737-2746.
4. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2012; 13:513-532.
5. Madan B, Virshup DM. Targeting Wnts at the source-new mechanisms, new biomarkers, new drugs. Mol Cancer Ther. 2015; 14:1087-1094.
6. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275:1787-1790.
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87:159-170.
8. Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, Lowe SW. Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell. 2015; 161:1539-1552.
9. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011; 17:647-653.
10. Burgess AW, Faux MC, Layton MJ, Ramsay RG. Wnt signaling and colon tumorigenesis-a view from the periphery. Exp Cell Res. 2011; 317:2748-2758.
11. Serafino A, Moroni N, Zonfrillo M, Andreola F, Mercuri L, Nicotera G, Nunziata J, Ricci R, Antinori A, Rasi G, Pierimarchi P. WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget. 2014; 5:978-992. doi: 10. 18632/oncotarget. 1571.
12. Petrov KG, Zhang YM, Carter M, Cockerill GS, Dickerson S, Gauthier CA, Guo Y, Mook RA, Jr., Rusnak DW, Walker AL, Wood ER, Lackey KE. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg Med Chem Lett. 2006; 16:4686-4691.
13. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem. 2010; 53:1413-1437.
14. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett. 2001; 11:1911-1914.
15. Wu X, Li M, Qu Y, Tang W, Zheng Y, Lian J, Ji M, Xu L. Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg Med Chem. 2010; 18:3812-3822.
16. Chen Z, Venkatesan AM, Dehnhardt CM, Dos Santos O, Delos Santos E, Ayral-Kaloustian S, Chen L, Geng Y, Arndt KT, Lucas J, Chaudhary I, Mansour TS. 2,4-Diaminoquinazolines as inhibitors of beta-catenin/Tcf-4 pathway:Potential treatment for colorectal cancer. Bioorg Med Chem Lett. 2009; 19:4980-4983.
17. Mao Y, Lin N, Tian W, Han X, Han X, Huang Z, An J. Design, synthesis, and biological evaluation of new diaminoquinazolines as beta-catenin/Tcf4 pathway inhibitors. J Med Chem. 2012; 55:1346-1359.
18. Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, et al. Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem. 2010; 53:897-910.
19. Nencini A, Pratelli C, Quinn JM, Salerno M, Tunici P, De Robertis A, Valensin S, Mennillo F, Rossi M, Bakker A, Benicchi T, Cappelli F, Turlizzi E, et al. Structure-activity relationship and properties optimization of a series of quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway. Eur J Med Chem. 2015; 95:526-545.
20. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A. 2001; 98:14973-14978.
21. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2001; 22:1172-1183.
22. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem. 2002; 277:21657-21665.
23. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 2002; 22:1184-1193.
24. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999; 96:5522-5527.
25. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398:422-426.
26. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003; 362:205-209.
27. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-cateninmediated survivin gene expression. Oncogene. 2005; 24:3619-3631.
28. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013; 110:20224-20229.
29. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013; 110:12649-12654.
30. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM, DasGupta R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011; 108:5954-5963.
31. Watanabe K, Dai X. Winning WNT: race to Wnt signaling inhibitors. Proc Natl Acad Sci U S A. 2011; 108:5929-5930.
32. Lu W, Kim KA, Liu J, Abo A, Feng X, Cao X, Li Y. R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression. FEBS Lett. 2008; 582:643-650.
33. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS One. 2011; 6:e29290.
34. Bafico A, Gazit A, Wu-Morgan SS, Yaniv A, Aaronson SA. Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene. 1998; 16:2819-2825.